跳至主要内容
临床试验/NCT03259269
NCT03259269已完成不适用

endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid

Partners in Health16 个研究点 分布在 14 个国家目标入组 2,804 人开始时间: 2015年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
2,804
试验地点
16
主要终点
End of treatment outcome

研究概览

简要总结

This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB. The information gathered in this study will inform doctors how best to use these TB drugs in the future.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Any patient who receives a treatment regimen containing bedaquiline or delamanid at an endTB site will be invited to participate in this observational study, regardless of age or gender.
  • Any patient who signs the study informed consent form will be included in the study.

排除标准

  • Refusal to participate in the study.

结局指标

主要结局

End of treatment outcome

时间窗: 20 - 24 months of treatment

Final outcomes: cured, treatment completed, treatment failed, lost to follow-up, died, not evaluated

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验